Tech Times on MSN
BioNTech slashes 2026 revenue guidance by €700M as COVID vaccine sales crater
BioNTech earnings 2026 showed a stunning €700 million revenue guidance cut, slashing its full-year outlook to €1.6–1.9 ...
MPR
FDA Drug Approval Decisions Expected in September 2026
Five major FDA Priority Review decisions are scheduled for September 2026, targeting rare genetic neurological conditions, FGFR2-mutated cholangiocarcinoma, and adolescent obstructive hypertrophic ...
Welltica+ on MSN
FDA clears a new engineered virus therapy for treatment-resistant advanced melanoma
Tudriqev pairs a modified herpes virus with nivolumab for melanoma that stopped responding to immunotherapy.
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue ...
What would it take to get peptides on the shelf?
An FDA advisory panel recently voted to green-light some popular peptides. The decision brought enormous attention to the ...
Spectrum News NY1
City reopens some streets as crews work to stabilize Midtown building
City officials announced late Tuesday that the frozen zone around the unstable Manhattan building has been reduced, allowing some pedestrians and traffic back into the area. Ahmed Tigani, commissioner ...
RFK Jr.’s Falsehood-Filled CNN Interview
In a contentious interview on CNN's "State of the Union," Health and Human Services Secretary Robert F. Kennedy Jr. made ...
Hemophilia News Today
Approved treatment controls bleeding for up to 5 years in hemophilia A
The approved treatment Hemlibra maintained low bleeding rates for up to five years in people with hemophilia A, according to ...
Targeted Oncology
Gedatolisib Combinations Nearly Double PFS in PIK3CA-Mutant Breast Cancer
Study 2 randomized PIK3CA-mutant patients 3:3:1 to gedatolisib/palbociclib/fulvestrant, gedatolisib/fulvestrant, or alpelisib/fulvestrant, using PFS for triplet vs ...